trial

Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids

NCTId NCT00205712
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 40 (actual)
Sponsored by Washington University School of Medicine
Primary completion 2007-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2003-02
Primary completion
2007-10
Eligibility
ALL · 7 Years · 17 Years

Interventions & indications

Drugs
KetamineDexmedetomidine

Sponsors

Washington University School of MedicineLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
John W. Newcomer, M.D.Principal Investigator

Sites

1 total
St Louis, United States

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE4
Primary Completion Date
2007-10
Status
COMPLETED
relationships
The graph out of here
drug
Ketamine
drug
Dexmedetomidine
drug
lead_sponsor
Washington University School of Medicine
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Psychoses, Substance-Induced
indication
Memory Disorders
indication
Psychoses, Substance-Induced
indication
investigator
John W. Newcomer, M.D.
person